Status:
COMPLETED
Real World Use of Emicizumab in Infants and Children Ages 0-3 Years With Hemophilia A
Lead Sponsor:
Montefiore Medical Center
Collaborating Sponsors:
Genentech, Inc.
Regional Comprehensive Hemophilia Treatment Center (Mount Sinai)
Conditions:
Hemophilia A
Eligibility:
All Genders
Up to 36 years
Brief Summary
Hemophilia A (HA) is a rare congenital bleeding disorder characterized by coagulation factor VIII deficiency. In severe HA, defined as plasma FVIII clotting activity \< 1%, bleeding may frequently occ...
Detailed Description
A questionnaire to elucidate the dosing, frequency and indication for the use of emicizumab in patients with Hemophilia A (mild, moderate or severe) ages 0-3 years has been developed. Data on any pre-...
Eligibility Criteria
Inclusion
- Patients must meet the following criteria for study entry:
- Patients who have been prescribed Emicizumab
- Patients who are 0-36 months of age at the time of starting treatment with Emicizumab
- Diagnosis of congenital mild, moderate or severe hemophilia with or without an inhibitor
Exclusion
- Patients with acquired Hemophilia A
- Patients with Hemophilia A and another congenital or acquired bleeding disorder.
Key Trial Info
Start Date :
August 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 18 2025
Estimated Enrollment :
71 Patients enrolled
Trial Details
Trial ID
NCT05248594
Start Date
August 1 2024
End Date
July 18 2025
Last Update
September 8 2025
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Connecticut Children's Hemophilia Treatment Center - Connecticut Children's Medical Center
Hartford, Connecticut, United States, 06106
2
Yale Hemophilia Treatment Center
New Haven, Connecticut, United States, 06510
3
Dartmouth Hitchcock Hemophilia Center - Mary Hitchcock Memorial Hospital
Lebanon, New Hampshire, United States, 03766
4
Newark Beth Israel
Newark, New Jersey, United States, 07112